Reliability on bioequivalence test to be strengthened

Published: 2002-10-10 07:00:00

Updated: 2002-10-10 07:00:00

The Korea Food and Drug Administration (KFDA) said that although it allows the corresponding pharmaceutical firms to perform the bioequivalence tests using their existing labs and personnel in a bid to promote the tests, they will be only permitted to analyze the plasma concentration of test drug...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK